IRCT20121216011763N57 IRCT 2023-03-29 Esfahan University of Medical Sciences The effect of co-supplementation with alpha-linolenic acid and L-carnitine in migraine Investigating the effect of co-supplementation with alpha-linolenic acid and L-carnitine on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life in women with migraine 2023-05-06 anticipated 80 Complete https://irct.ir/trial/69303 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The samples will be randomly placed in one of the four intervention or control groups using permuted block randomization, with blocks of 4. In order to distribute patients into intervention and control groups, first, people are classified into two states in terms of age (less than 35 years/35 years and older). Then, people with the same conditions will be randomly assigned to one of the intervention and control groups. Also, the researcher evaluating the intended outcomes is unaware of the random allocation process and the type of treatment performed, Blinding description: The study will be conducted as a three-blind study as follows: Medicines and placebo will be provided to all groups in completely identical containers without name labels, prepared in the same color and smell, and coded based on random allocation by the researcher. Therefore, none of the patients were aware of the assigned treatment and will not be informed until the end of the study. Also, the researcher evaluating the intended outcomes is unaware of the random allocation process and the type of treatment performed. 3 Migraine. Intervention 1: Intervention group: An alphal-inolenic acid supplement (daily 1000 mg flaxseed oil, one capsule containing 350 mg alphalinolenic acid) and L-carnitine supplement (500 mg L-carnitine). Intervention 2: Control group: Alpha-linolenic acid placebo (paraffin oil, one 1000 mg capsule per day) and L-carnitine placebo (maltodextrin, one 500 mg tablet per day). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information